RBC Capital Initiates Coverage on GE HealthCare with Bullish Outlook
Investment bank RBC Capital Markets has officially initiated coverage on GE HealthCare Technologies Inc. (NASDAQ: GEHC), assigning the medical technology giant an "Outperform" rating alongside a price target of $96.00. The move signals Wall Street’s continued confidence in the company’s independent trajectory following its highly publicized spin-off from General Electric in early 2023. According to the initiating note, RBC analysts view GE HealthCare as a premier vehicle for investors seeking exposure to the secular growth of global healthcare infrastructure, precision medicine, and clinical artificial intelligence.
Since transitioning to a standalone entity, Chicago-based GE HealthCare has focused heavily on expanding its high-margin segments, particularly in advanced imaging (MRI and CT scans), ultrasound, and pharmaceutical diagnostics. The company has successfully navigated post-pandemic supply chain disruptions, translating a robust order backlog into steady revenue growth. RBC Capital’s analysts highlighted that GE HealthCare is uniquely positioned to capitalize on a multi-year equipment replacement cycle as hospitals globally seek to upgrade aging diagnostic fleets to improve operational efficiency amidst persistent healthcare labor shortages.
"GE HealthCare is no longer constrained by the capital allocation priorities of a broader industrial conglomerate," noted the research team at RBC. "The company’s renewed focus on R&D investment, particularly in integrating AI and digital workflow solutions into their imaging hardware, provides a clear path toward sustained margin expansion." Analysts also pointed to the firm's strong balance sheet and its disciplined approach to tuck-in acquisitions, such as its recent strategic purchases in the ultrasound and AI-guided therapy spaces, as key drivers that will help the company outpace legacy competitors.
Looking ahead, the investment firm expects GE HealthCare to deliver consistent mid-single-digit organic revenue growth and steady free cash flow conversion over the next three to five years. While macroeconomic headwinds, including elevated interest rates and tighter capital spending budgets at mid-tier hospital systems, remain a monitoring point, RBC believes GEHC's diversified geographic footprint and essential-service contracts will buffer against cyclical downturns. This initiation adds to a growing consensus among institutional analysts who view the spin-off as a highly successful unlock of shareholder value in the medtech sector.